Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > 15$ US Target reiterated today as well

<< Previous

Bullboard Posts

Next >>

Comment by HCallahann44on May 21, 2021 3:59pm

223 Views

Post# 33249552

RE:RE:RE:RE:15$ US Target reiterated today as well

Actuarial---you are forgetting that these study patients are on their last legs with immune systems destroyed by chemo and other modern medicine garbage...who knows what pela could do in someone who doesn't start with chemo....since it primes the immune system...not much immune system left in panc patients..

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland